Healthcare overhaul may threaten California's safety net









Millions of uninsured Californians will gain medical coverage under the national healthcare overhaul beginning in January, but Guadalupe Luna won't be one of them.


Luna, an illegal immigrant and tamale vendor in Los Angeles, doesn't qualify. So she will continue going to the clinic where she has received free care for more than 20 years: Los Angeles County's Hudson Comprehensive Health Center. There, publicly funded doctors will help manage her diabetes and high cholesterol.


An estimated 3 million to 4 million Californians — about 10% of the state's population — could remain uninsured even after the healthcare overhaul law takes full effect. The burden of their care will fall to public hospitals, county health centers and community clinics. And those institutions may be in jeopardy.





County health leaders and others say the national health law has had the unintended consequence of threatening the financial stability of the state's safety net.


Newly insured patients who no longer have to rely on public hospitals and clinics may seek care elsewhere, meaning a loss in revenue, they say. And under the federal law, some of the funding that goes to safety-net hospitals is also set to decrease.


Now, as the state scrambles to create the new healthcare infrastructure, Gov. Jerry Brown is proposing to take back another crucial pot of money that counties have depended on for more than two decades to care for the uninsured.


"Safety net providers are imperative ... and some of their funding streams are in serious danger," said Lucien Wilson, director of the Insure the Uninsured Project, a consumer organization.


Melissa Stafford Jones, president and chief executive of the California Assn. of Public Hospitals and Health Systems, said many of the patients who are uninsured now still won't have coverage next year. "Those communities are still going to need care, and we need to have a safety net to serve them," she said.


Under the healthcare overhaul, the state could enroll as many as 1.4 million additional residents in Medi-Cal, its program for the poor and disabled, and sign up 2.1 million others for subsidized private insurance through a marketplace known as Covered California, according to a recent UC Berkeley report.


About a quarter of those left uninsured will be undocumented immigrants, and nearly three-quarters will be U.S. citizens or green-card holders, according to the report. Some already qualify for Medi-Cal but don't receive it; others will be eligible to buy subsidized healthcare through Covered California but won't be able to afford it.


Martin Garcia, 39, a U.S. citizen with five children, said he doesn't know if he could get Medi-Cal now or what he might qualify for next year. Garcia lost his job and insurance in 2010 and recently started going to the Hudson clinic in Los Angeles because of stomach pains.


Garcia needs hernia surgery, which he said he will receive at L.A. County-USC Medical Center, a public hospital. He said he was relieved to learn that he could get free healthcare through the county. Without it, he said, "I really don't know what I would do. I would probably head to Mexico."


Even with massive outreach by the state, it will take time for eligible people to learn about and enroll in the new coverage. During the early years, the demand for public health services is expected to remain high, and counties will be responsible, said report author Ken Jacobs, chairman of the UC Berkeley Center for Labor Research and Education.


To pay for care for the uninsured, counties have long relied on revenue from sales tax and vehicle license fees — a pot of money known as realignment funds. In fiscal year 2012, the funds amounted to an estimated $1.3 billion.


Brown argues that counties will no longer need all that money because so many of the uninsured will gain coverage under the federal law. At the same time, the governor's administration has said, the state will need the funds if it is going to run the expanded Medi-Cal program.


"There is going to be a fundamental shift in responsibility of healthcare to the state from the counties," said Toby Douglas, director of the state Department of Health Care Services. "There needs to be a realignment of county dollars."


The Legislative Analyst's Office released a report this month recommending that the state run the Medi-Cal expansion and that it take control of some of the realignment funding to help pay for that expansion.


But county health directors argue that the state is just trying to balance its budget on the backs of safety-net systems. They say the counties already struggle to meet demand and contend the state should not take the money before it's clear how many people will sign up for Medi-Cal and how much savings there will be for counties.


"The state needs money, and they see this as an opportunity to get it," said Mitch Katz, director of the Los Angeles County Department of Health Services. "I think it is completely unreasonable."


If the state does take back the realignment funding, counties such as Los Angeles that run their own hospitals and clinics could be seriously affected, he said.


Alex Briscoe, director of Alameda County's Health Care Services Agency, said the state proposal shows a "fundamental misunderstanding" of the pressures facing safety-net systems. About 100,000 people might remain uninsured in the county, he said. "If the state takes the money, who is going to pay that care?"


In addition, Briscoe said the state doesn't have any justification for taking the money because the Medi-Cal expansion is 100% covered by the federal government for the first three years.


Who ends up paying doesn't matter to Luna, the tamale vendor. But without the Hudson clinic, the 43-year-old said, her diabetes would spiral out of control.


"I don't have anywhere else to go," she said. "I have to come here."


Luna is one of about 42,000 patients who go to the clinic and urgent care center to manage their chronic diseases, get their children vaccinated, check their eyes and monitor their pregnancies.


Hudson's administrator, Michael Mills, said that even after the healthcare law takes full effect, the clinic will be vital to the community. Nearly half its patients now are uninsured, and many will remain without coverage next year.


"Those are our patients," Medical Director Rona Molodow said. "Those are the people the county has traditionally served."


anna.gorman@latimes.com





Read More..

South Korea’s Park Geun-hye Warns North Against Nuclear Pursuits





SEOUL, South Korea — Park Geun-hye, the daughter of a late military strongman, was sworn in Monday as South Korea’s first female president, warning North Korea that the primary victim of its pursuit of nuclear weapons and long-range missiles will be the isolated country itself.




“North Korea’s recent nuclear test is a challenge to the survival and future of the Korean people, and there should be no mistake that the biggest victim will be none other than North Korea itself,” Ms. Park said in her inaugural address in front of the National Assembly building in Seoul.


She urged North Korea to abandon its nuclear ambitions without delay, “instead of wasting its resources on nuclear and missile development and continuing to turn its back to the world in self-imposed isolation.”


Her motorcade’s arrival Monday at the presidential Blue House marked a triumphant moment not just for Ms. Park but for her family. Ms. Park, 61, was returning to her childhood home, 34 years after the assassination of her father, Park Chung-hee, a divisive figure even now. Mr. Park’s 18-year rule was credited with rapidly raising South Korea’s economy from postwar devastation, but his iron-fisted governance was increasingly maligned as the country evolved toward democracy.


Ms. Park was elected in December thanks largely to the support of South Koreans in their 50s and older. Many younger voters were vehemently opposed to her candidacy, saying she represented a return to the past.


North Korea, meanwhile, has again become a prime national security concern. A week before Ms. Park’s election, the North launched a satellite into orbit in defiance of United Nations resolutions. On Feb. 12, it conducted a third nuclear test. The two events have heightened fears that years of efforts by Washington and its allies to rein in the North’s nuclear ambitions have failed, even as Pyongyang appears to have made progress toward achieving the capability to make long-range nuclear missiles.


Speaking Monday before a large crowd — which earlier had been entertained by the rapper Psy, famous for the song “Gangnam Style” — Ms. Park also addressed economic concerns, a major issue in the election. She said her tasks as president would include “achieving economic rejuvenation, the happiness of the people and the flourishing of our culture.”


In a comment reminiscent of her father, she called for a “second miracle on the Han River.” Seoul, which straddles the Han, began transforming itself into an industrialized metropolis under her father, who sought economic growth at all costs and nurtured a handful of family-controlled companies, such as Samsung and Hyundai, as the engines of an export-driven economy.


Now, as his daughter takes office, one of the biggest complaints among ordinary South Koreans is of widening economic inequality, particularly those conglomerates’ overpowering influence on smaller businesses — a grievance Mr. Park addressed in her speech, saying that a second Han River “miracle” should be based on “economic democratization.”


She promised policies designed to strengthen small and medium-sized enterprises so that “such businesses can prosper alongside large companies.” She said, “By rooting out various unfair practices and rectifying the misguided habits of the past which have frustrated small business owners and small and medium-sized enterprises, we will provide active support to ensure that everyone can live up to their fullest potential, regardless of where they work or what they do for a living.”


Read More..

Les Misérables Stars Oscar Gowns: Love 'Em or Leave 'Em







Style News Now





02/24/2013 at 09:30 PM ET











Oscars 2013 Anne Hathaway Amanda Seyfried GownsJason Merritt/Getty, John Shearer/AP


Though Anne Hathaway and Amanda Seyfried got a thumbs-up from the PEOPLE StyleWatch team for their bubbly red carpet demeanors and terrific hair and makeup, their dresses inspired decidedly mixed reactions.


Hathaway said she picked her baby pink Prada column just hours before the ceremony. The dress had a fun, criss-crossed back and the Tiffany & Co. diamonds she draped herself with were spectacular, but the bodice of the dress was, er, possibly not safe for work when seen up close on the red carpet.


Seyfried’s lilac Alexander McQueen gown with silver leaf embroidery was a sophisticated pick (and a challenging one: she mentioned that the corset was “pushing her organs out of her body”) but the fit wasn’t exact — and if you’re reading, Amanda, we’d really love to see you in more color.


RELATED PHOTOS: The Best Dressed List


Since we’re ambivalent about these dresses, we want you to vote in the polls below, and tell us: What do you think of Hathaway and Seyfried’s Oscar gowns? If you don’t like them, what would you want to see them wear?










Read More..

FDA approves new targeted breast cancer drug


WASHINGTON (AP) — The Food and Drug Administration has approved a first-of-a-kind breast cancer medication that targets tumor cells while sparing healthy ones.


The drug Kadcyla from Roche combines the established drug Herceptin with a powerful chemotherapy drug and a third chemical linking the medicines together. The chemical keeps the cocktail intact until it binds to a cancer cell, delivering a potent dose of anti-tumor poison.


Cancer researchers say the drug is an important step forward because it delivers more medication while reducing the unpleasant side effects of chemotherapy.


"This antibody goes seeking out the tumor cells, gets internalized and then explodes them from within. So it's very kind and gentle on the patients — there's no hair loss, no nausea, no vomiting," said Dr. Melody Cobleigh of Rush University Medical Center. "It's a revolutionary way of treating cancer."


Cobleigh helped conduct the key studies of the drug at the Chicago facility.


The FDA approved the new treatment for about 20 percent of breast cancer patients with a form of the disease that is typically more aggressive and less responsive to hormone therapy. These patients have tumors that overproduce a protein known as HER-2. Breast cancer is the second most deadly form of cancer in U.S. women, and is expected to kill more than 39,000 Americans this year, according to the National Cancer Institute.


The approval will help Roche's Genentech unit build on the blockbuster success of Herceptin, which has long dominated the breast cancer marketplace. The drug had sales of roughly $6 billion last year.


Genentech said Friday that Kadcyla will cost $9,800 per month, compared to $4,500 per month for regular Herceptin. The company estimates a full course of Kadcyla, about nine months of medicine, will cost $94,000.


FDA scientists said they approved the drug based on company studies showing Kadcyla delayed the progression of breast cancer by several months. Researchers reported last year that patients treated with the drug lived 9.6 months before death or the spread of their disease, compared with a little more than six months for patients treated with two other standard drugs, Tykerb and Xeloda.


Overall, patients taking Kadcyla lived about 2.6 years, compared with 2 years for patients taking the other drugs.


FDA specifically approved the drug for patients with advanced breast cancer who have already been treated with Herceptin and taxane, a widely used chemotherapy drug. Doctors are not required to follow FDA prescribing guidelines, and cancer researchers say the drug could have great potential in patients with earlier forms of breast cancer


Kadcyla will carry a boxed warning, the most severe type, alerting doctors and patients that the drug can cause liver toxicity, heart problems and potentially death. The drug can also cause severe birth defects and should not be used by pregnant women.


Kadcyla was developed by South San Francisco-based Genentech using drug-binding technology licensed from Waltham, Mass.-based ImmunoGen. The company developed the chemical that keeps the drug cocktail together and is scheduled to receive a $10.5 million payment from Genentech on the FDA decision. The company will also receive additional royalties on the drug's sales.


Shares of ImmunoGen Inc. rose 2 cents to $14.32 in afternoon trading. The stock has ttraded in a 52-wek range of $10.85 to $18.10.


Read More..

Mahony answers questions under oath about clergy sex abuse cases









A "relatively unflappable" Cardinal Roger Mahony answered questions under oath for more than 3 1/2 hours Saturday about his handling of clergy sex abuse cases, according to the lawyer who questioned the former archbishop.


"He remained calm and seemingly collected at all times," said attorney Anthony De Marco, who represents a man suing the Los Angeles Archdiocese over abuse he alleges he suffered at the hands of a priest who visited his parish in 1987.


Mahony has been deposed many times in the past, but Saturday's session was the first time he had been asked about recently released internal church records that show he shielded abusers from law enforcement.





De Marco declined to detail the questions he asked or the answers the cardinal provided, citing a judge's protective order.


The deposition occurred just before Mahony was to board a plane for Italy to vote in the conclave that will elect the next pope. In a Twitter post Friday, Mahony wrote that it was "just a few short hours before my departure for Rome."


Church officials did not return requests for comment.


The case, set for trial in April, concerns a Mexican priest, Nicholas Aguilar Rivera. Authorities believe he molested at least 26 children during a nine-month stay in Los Angeles.


Recently released church files show Aguilar Rivera fled to Mexico after a top Mahony aide, Thomas Curry, warned him that parents were likely to go the police and that he was in "a good deal of danger." Aguilar Rivera remains a fugitive in Mexico.


The archdiocese had agreed that Mahony could be questioned for four hours about the Aguilar Rivera case and 25 other priests accused in the same period. De Marco said he did not get to ask everything he wanted and would seek additional time after the cardinal returned from the Vatican.


Past depositions of Mahony have eventually become public, and De Marco said he would follow court procedures to seek the release of a transcript of Saturday's deposition.


Meanwhile, a Catholic organization Saturday delivered a petition with thousands of signatures asking that Mahony recuse himself from the conclave in Rome.


The group, Catholics United, collected nearly 10,000 signatures making "a simple request" that the former archbishop of Los Angeles not participate in the process because of the priest abuse scandals that happened under his watch, said Chris Pumpelly, communications director for Catholics United.


The petition was delivered Saturday to St. Charles Borromeo in North Hollywood, where the cardinal resides. It was accepted by a church staff member.


After delivering the petition, organizers attended Mass at the parish to pray for healing and for the future of the church.


harriet.ryan@latimes.com


Times staff writer Rick Rojas contributed to this report.





Read More..

Car Bomb Hits Intelligence Agency in Afghanistan







KABUL, Afghanistan (AP) — A series of early morning attacks hit eastern Afghanistan Sunday, with three separate suicide bombings in outlying provinces and a shootout between security forces and a would-be attacker in the capital city of Kabul.




The deadliest attack was a suicide car bombing at a state intelligence site just after sunrise in the eastern city of Jalalabad. In that attack, a car approached the gate of a compound used by the National Directorate of Security and exploded, killing two guards and wounding three others, said regional government spokesman Ahmad Zia Abdulzai. The building was damaged in the attack, he added.


Taliban spokesman Zabiullah Mujahid claimed responsibility for the bombing.


Shortly before the Jalalabad attack, an assailant detonated a van packed with explosives at a highway police checkpoint in Logar province, also in the east. That explosion wounded three police officers but no one was killed, said Deputy Police Chief Rais Khan Abdul Rahimzai.


In Kabul, meanwhile, police shot and killed a would-be suicide bomber who was trying to attack an intelligence agency office downtown, according to the city's deputy police chief, Gen. Mohammad Daud Amin. Intelligence agents spotted the bomber before he could detonate the explosives in his vehicle and shot him, Amin said.


The explosives in the vehicle were later defused, he added.


Later in the morning, a man wearing a suicide vest blew himself up outside the police headquarters for Baraki Barak district in Logar province. The man was stopped by police as he tried to force his way into the building, but still managed to detonate his vest, said Din Mohammad Darwesh, the provincial government spokesman.


One policeman was wounded in the Baraki Barak attack, Darwesh said.


Read More..

Breaking Dawn - Part 2 Sweeps the Razzies









02/23/2013 at 10:00 PM EST







Taylor Lautner and Mackenzie Foy, in Breaking Dawn – Part 2


Andrew Cooper, SMPSP/Summit


Who's misérable now?

The Twilight Saga: Breaking Dawn – Part 2, Adam Sandler and Rihanna are among the "winners" of the 33rd annual Golden Raspberry Awards – the Razzies – which are not so much handed out as they are thrown at those who are voted as perpetrating Hollywood's worst achievements of the year.

Breaking Dawn – Part 2, the fifth and final installment in Stephenie Meyer's vampire saga, was recognized in seven categories, including worst picture.

The flick's Kristen Stewart was also cited as worst actress; Taylor Lautner, worst supporting actor; Lautner and 12-year-old Mackenzie Foy, worst screen couple; the entire cast, including Robert Pattinson, worst screen ensemble, and Bill Condon, worst director.

In addition, the film, which since opening last November has taken in more than $828 million at the box office, was named worst sequel.

Sandler, who last year monopolized the Razzies – and set a record by winning in 10 categories with the "comedy" Jack & Jill – this year got only two awards: for worst actor of the year and worst screenplay, both for That's My Boy.

Unlike the Oscars, which keep voting tallies a secret and will be handed out Sunday night during a very glamorous event, founder and Head RAZZberry John Wilson announced Razzie recipients Saturday night in the utilitarian Continental Breakfast Room of the Holiday Inn Express Hollywood Walk of Fame hotel, near (and yet so far from) the Dolby Theatre, home of the Academy Awards.

Wilson revealed to the press that although Rihanna, as worst supporting actress in the movie Battleship, won her Razzie by a landslide, worst screenwriter Sandler only beat the authors of Breaking Dawn by a single vote.

It's close shaves like that that really make or break the Razzies.

Breaking Dawn – Part 2 Sweeps the Razzies| Oscars 2013, The Razzies 2013, Movies, Battleship, That's My Boy, News Franchises, Individual Class, Adam Sandler, Kristen Stewart, Rihanna, Robert Pattinson

Adam Sandler, in That's My Boy, and Rihanna, in Battleship

Columbia; Universal

The 85th annual Academy Awards will air live on ABC starting at 7 p.m. ET/4 p.m. PT on Sunday, Feb. 24, from the Dolby Theatre in Hollywood.
Read More..

FDA approves new targeted breast cancer drug


WASHINGTON (AP) — The Food and Drug Administration has approved a first-of-a-kind breast cancer medication that targets tumor cells while sparing healthy ones.


The drug Kadcyla from Roche combines the established drug Herceptin with a powerful chemotherapy drug and a third chemical linking the medicines together. The chemical keeps the cocktail intact until it binds to a cancer cell, delivering a potent dose of anti-tumor poison.


Cancer researchers say the drug is an important step forward because it delivers more medication while reducing the unpleasant side effects of chemotherapy.


"This antibody goes seeking out the tumor cells, gets internalized and then explodes them from within. So it's very kind and gentle on the patients — there's no hair loss, no nausea, no vomiting," said Dr. Melody Cobleigh of Rush University Medical Center. "It's a revolutionary way of treating cancer."


Cobleigh helped conduct the key studies of the drug at the Chicago facility.


The FDA approved the new treatment for about 20 percent of breast cancer patients with a form of the disease that is typically more aggressive and less responsive to hormone therapy. These patients have tumors that overproduce a protein known as HER-2. Breast cancer is the second most deadly form of cancer in U.S. women, and is expected to kill more than 39,000 Americans this year, according to the National Cancer Institute.


The approval will help Roche's Genentech unit build on the blockbuster success of Herceptin, which has long dominated the breast cancer marketplace. The drug had sales of roughly $6 billion last year.


Genentech said Friday that Kadcyla will cost $9,800 per month, compared to $4,500 per month for regular Herceptin. The company estimates a full course of Kadcyla, about nine months of medicine, will cost $94,000.


FDA scientists said they approved the drug based on company studies showing Kadcyla delayed the progression of breast cancer by several months. Researchers reported last year that patients treated with the drug lived 9.6 months before death or the spread of their disease, compared with a little more than six months for patients treated with two other standard drugs, Tykerb and Xeloda.


Overall, patients taking Kadcyla lived about 2.6 years, compared with 2 years for patients taking the other drugs.


FDA specifically approved the drug for patients with advanced breast cancer who have already been treated with Herceptin and taxane, a widely used chemotherapy drug. Doctors are not required to follow FDA prescribing guidelines, and cancer researchers say the drug could have great potential in patients with earlier forms of breast cancer


Kadcyla will carry a boxed warning, the most severe type, alerting doctors and patients that the drug can cause liver toxicity, heart problems and potentially death. The drug can also cause severe birth defects and should not be used by pregnant women.


Kadcyla was developed by South San Francisco-based Genentech using drug-binding technology licensed from Waltham, Mass.-based ImmunoGen. The company developed the chemical that keeps the drug cocktail together and is scheduled to receive a $10.5 million payment from Genentech on the FDA decision. The company will also receive additional royalties on the drug's sales.


Shares of ImmunoGen Inc. rose 2 cents to $14.32 in afternoon trading. The stock has ttraded in a 52-wek range of $10.85 to $18.10.


Read More..

Paroled sex offenders disarming tracking devices









SACRAMENTO — Thousands of paroled child molesters, rapists and other high-risk sex offenders in California are removing or disarming their court-ordered GPS tracking devices — and some have been charged with new crimes including sexual battery, kidnapping and attempted manslaughter.


The offenders have discovered that they can disable the monitors, often with little risk of serving time for it, a Times investigation has found. The jails are too full to hold them.


"It's a huge problem," said Fresno parole agent Matt Hill. "If the public knew, they'd be shocked."





More than 3,400 arrest warrants for GPS tamperers have been issued since October 2011, when the state began referring parole violators to county jails instead of returning them to its packed prisons. Warrants increased 28% in 2012 compared to the 12 months before the change in custody began. Nearly all of the warrants were for sex offenders, who are the vast majority of convicts with monitors, and many were for repeat violations.


The custody shift is part of Gov. Jerry Brown and the legislature's "realignment" program, to comply with court orders to reduce overcrowding in state prisons. But many counties have been under their own court orders to ease crowding in their jails.


Some have freed parole violators within days, or even hours, of arrest rather than keep them in custody. Some have refused to accept them at all.


Before prison realignment took effect, sex offenders who breached parole remained behind bars, awaiting hearings that could send them back to prison for up to a year. Now, the maximum penalty is 180 days in jail, but many never serve that time.


With so little deterrent, parolees "certainly are feeling more bold," said Jack Wallace, an executive at the California Sex Offender Management Board.


Rithy Mam, a convicted child stalker, was arrested three times in two months after skipping parole and was freed almost immediately each time. After his third release, his GPS alarm went off and he vanished, law enforcement records show.


The next day, he turned up in a Stockton living room where a 15-year-old girl was asleep on the couch, police said. The girl told police she awoke to find the stranger staring at her and that he asked "Wanna date?" before leaving the home.


Police say Mam went back twice more that week and menaced the girl and her 13-year-old sister, getting in by giving candy to a toddler, before authorities recaptured him in a local park. He is in custody on new charges of child molestation.


Californians voted in 2006 to require that high-risk sex offenders be tracked for life with GPS monitors strapped to their bodies.


The devices are programmed to record offenders' movements and are intended, at least in part, to deter them from committing crimes. The devices, attached to rubber ankle straps embedded with fiber-optic cable, transmit signals monitored by a private contractor.


They are easy to cut off, but an alarm is triggered when that happens, as it is when they are interfered with in other ways or go dead, or when an offender enters a forbidden area such as a school zone or playground. The monitoring company alerts parole agents by text message or email.


Arrest warrants for GPS tamperers are automatically published online. The Times reviewed that data as well as thousands of jail logs, court documents and criminal histories provided by confidential sources. The records show that the way authorities handle violators can vary significantly by county.


San Bernardino County releases more inmates early from its cramped jails than any other county in California, according to state reports. But sex offenders who violate parole there generally serve their terms. A spokeswoman said the county closely reviews criminal histories, and those with past sex offenses are ineligible for early release.


By contrast, parole violators in San Joaquin County are often set free within a day of arrest.


A review of the county's jail logs shows that nine of the 15 sex offenders arrested for violating parole in December and January were let out within 24 hours, including seven who immediately tampered with their trackers and disappeared. One of the nine, a convicted rapist named Robert Stone, was arrested two weeks later on kidnapping charges and returned to jail, where he remains.


Raoul Leyva, a sex offender with a history of beating women, was arrested in April for fleeing parole and ordered to remain jailed for 100 days. He was out in 16 days and soon bolted again, after allowing the battery on his device to go dead, according to the documents reviewed by The Times.


Less than two weeks later, a drug dealer led police to a Stockton apartment where Leyva's girlfriend, 20-year-old Brandy Arreola, had lain for days on the floor, severely beaten and in a coma. Now brain damaged and confined to a wheelchair, Arreola spends her time watching cartoons.





Read More..

Chinese City Reports Second Bird Flu Fatality





HONG KONG — China has reported a second fatality from the deadly H5N1 bird flu, a 31-year-old man who died of organ failure in the south-central Chinese city of Guiyang.




The flu, which is circulated in poultry and birds, has infected only 600 humans in the last decade, but has proven fatal in half the cases, so public health officials closely monitor its transmission. Scientists fear that the flu could mutate into a form that is highly contagious in humans.


In the most recent case, the man died Friday at a hospital in Guiyang. That city is also where a 21-year old woman died on Feb. 13. The official Xinhua news agency said that both victims had been in close contact with birds, the most common means of transmission.


The news agency added that 110 people who had been exposed to the victims had been released from quarantine.


As of Feb. 15, there have been 10 cases of H5N1 reported worldwide since the start of the year, according to the World Health Organization. In all of 2012, there were 32 cases worldwide.


Read More..